Chugai Launches Perjeta For HER2-Positive Cancer In Japan
This article was originally published in PharmAsia News
Executive Summary
Chugai has launched 420mg/14ml intravenous infusion Perjeta (pertuzumab) for the treatment of inoperable or recurrent HER2-positive breast cancer in Japan.